Somapacitan in Children Born SGA: 52-week Efficacy, Safety, and IGF-I Response Results from the Phase 2 REAL5 Study.

Anders Juul Philippe F Backeljauw Michael Højby Rasmussen Jan Frystyk Masanobu Kawai Rasmus Juul Kildemoes Anders Krogh Lemminger Agnès Linglart Nehama Zuckerman Levin Reiko Horikawa

Published in: The Journal of clinical endocrinology and metabolism (2024)

A sustained dose-dependent growth response was demonstrated for somapacitan after 52 weeks of treatment. Overall, somapacitan 0.24 mg/kg/week provides similar efficacy, safety, and tolerability, as well as comparable bioactive and total IGF-I response, as daily GH (0.067 mg/kg/day) in children born SGA.

Keyphrases

young adults
gestational age
physical activity
growth hormone
low birth weight
placebo controlled
binding protein
preterm birth
combination therapy